These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 35079240)

  • 21. Implementing harm reduction in non-urban communities affected by opioids and polysubstance use: A qualitative study exploring challenges and mitigating strategies.
    Childs E; Biello KB; Valente PK; Salhaney P; Biancarelli DL; Olson J; Earlywine JJ; Marshall BDL; Bazzi AR
    Int J Drug Policy; 2021 Apr; 90():103080. PubMed ID: 33340947
    [TBL] [Abstract][Full Text] [Related]  

  • 22. 'Why would we not want to keep everybody safe?' The views of family members of people who use drugs on the implementation of drug consumption rooms in Scotland.
    Parkes T; Price T; Foster R; Trayner KMA; Sumnall HR; Livingston W; Perkins A; Cairns B; Dumbrell J; Nicholls J
    Harm Reduct J; 2022 Aug; 19(1):99. PubMed ID: 36038919
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A qualitative examination of naloxone access in three states: Connecticut, Kentucky, and Wisconsin.
    Spector AL; Galletly CL; Christenson EA; Montaque HDG; Dickson-Gomez J
    BMC Public Health; 2022 Jul; 22(1):1387. PubMed ID: 35854278
    [TBL] [Abstract][Full Text] [Related]  

  • 24. First Responders' Views of Naloxone: Does Stigma Matter?
    Kruis NE; McLean K; Perry P; Nackley MK
    Subst Use Misuse; 2022; 57(10):1534-1544. PubMed ID: 35791871
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A new brief opioid stigma scale to assess perceived public attitudes and internalized stigma: Evidence for construct validity.
    Yang LH; Grivel MM; Anderson B; Bailey GL; Opler M; Wong LY; Stein MD
    J Subst Abuse Treat; 2019 Apr; 99():44-51. PubMed ID: 30797393
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Investigating opioid preference to inform safe supply services: A cross sectional study.
    Ferguson M; Parmar A; Papamihali K; Weng A; Lock K; Buxton JA
    Int J Drug Policy; 2022 Mar; 101():103574. PubMed ID: 35007878
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The association between stigmatizing attitudes towards depression and help seeking attitudes in college students.
    Conceição V; Rothes I; Gusmão R
    PLoS One; 2022; 17(2):e0263622. PubMed ID: 35180243
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Inequities in access to primary care among opioid recipients in Ontario, Canada: A population-based cohort study.
    Gomes T; Campbell TJ; Martins D; Paterson JM; Robertson L; Juurlink DN; Mamdani M; Glazier RH
    PLoS Med; 2021 Jun; 18(6):e1003631. PubMed ID: 34061846
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Perception of pharmacy students toward opioid-related disorders and roles of community pharmacists: A French nationwide cross-sectional study.
    Balayssac D; Pereira B; Cuq P; Douris J; Ferrari L; Boutet-Robinet E; Lechevrel M; Demeilliers C; Rat P; Coudoré F; Verron E; Lacarelle B; Guitton J; Courtois A; Allorge D; Pain S; Guerbet M; Collin A; Vennat B; Brousse G; Authier N; Laporte C
    Subst Abus; 2021; 42(4):706-715. PubMed ID: 33320801
    [No Abstract]   [Full Text] [Related]  

  • 30. Reasons People Who Use Opioids Do Not Accept or Carry No-Cost Naloxone: Qualitative Interview Study.
    Bennett AS; Freeman R; Des Jarlais DC; Aronson ID
    JMIR Form Res; 2020 Dec; 4(12):e22411. PubMed ID: 33355094
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Opioid agonist therapy uptake among people who inject drugs: the findings of two consecutive bio-behavioral surveillance surveys in Iran.
    Nakhaeizadeh M; Abdolahinia Z; Sharifi H; Mirzazadeh A; Haghdoost AA; Shokoohi M; Baral S; Karamouzian M; Shahesmaeili A
    Harm Reduct J; 2020 Jul; 17(1):50. PubMed ID: 32698875
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Association between harm reduction strategies and healthcare utilization in patients on long-term prescribed opioid therapy presenting to acute healthcare settings: a protocol for a systematic review and meta-analysis.
    Deschamps J; Gilbertson J; Straube S; Dong K; MacMaster FP; Korownyk C; Montgomery L; Mahaffey R; Downar J; Clarke H; Muscedere J; Rittenbach K; Featherstone R; Sebastianski M; Vandermeer B; Lynam D; Magnussen R; Bagshaw SM; Rewa OG
    Syst Rev; 2019 Apr; 8(1):88. PubMed ID: 30953550
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Substance Use in Pregnancy: Identifying Stigma and Improving Care.
    Weber A; Miskle B; Lynch A; Arndt S; Acion L
    Subst Abuse Rehabil; 2021; 12():105-121. PubMed ID: 34849047
    [TBL] [Abstract][Full Text] [Related]  

  • 34. How are perceived stigma, self-stigma, and self-reliance related to treatment-seeking? A three-path model.
    Jennings KS; Cheung JH; Britt TW; Goguen KN; Jeffirs SM; Peasley AL; Lee AC
    Psychiatr Rehabil J; 2015 Jun; 38(2):109-116. PubMed ID: 25844914
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Implementation and sustainability of safe consumption sites: a qualitative systematic review and thematic synthesis.
    Yoon GH; Levengood TW; Davoust MJ; Ogden SN; Kral AH; Cahill SR; Bazzi AR
    Harm Reduct J; 2022 Jul; 19(1):73. PubMed ID: 35790994
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Perspectives of clients and providers on factors influencing opioid agonist treatment uptake among HIV-positive people who use drugs in Indonesia, Ukraine, and Vietnam: HPTN 074 study.
    Kiriazova T; Go VF; Hershow RB; Hamilton EL; Sarasvita R; Bui Q; Lancaster KE; Dumchev K; Hoffman IF; Miller WC; Latkin CA
    Harm Reduct J; 2020 Oct; 17(1):69. PubMed ID: 32998731
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Can a new formulation of opiate agonist treatment alter stigma?: Place, time and things in the experience of extended-release buprenorphine depot.
    Treloar C; Lancaster K; Gendera S; Rhodes T; Shahbazi J; Byrne M; Degenhardt L; Farrell M
    Int J Drug Policy; 2022 Sep; 107():103788. PubMed ID: 35816790
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Contested space in the pharmacy: public attitudes to pharmacy harm reduction services in the West of Scotland.
    Gidman W; Coomber R
    Res Social Adm Pharm; 2014; 10(3):576-87. PubMed ID: 24021859
    [TBL] [Abstract][Full Text] [Related]  

  • 39. "Like being put on an ice floe and shoved away": A qualitative study of the impacts of opioid-related policy changes on people who take opioids.
    Antoniou T; Ala-Leppilampi K; Shearer D; Parsons JA; Tadrous M; Gomes T
    Int J Drug Policy; 2019 Apr; 66():15-22. PubMed ID: 30685650
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prolonged-release opioid agonist therapy: qualitative study exploring patients' views of 1-week, 1-month, and 6-month buprenorphine formulations.
    Neale J; Tompkins CNE; Strang J
    Harm Reduct J; 2019 Apr; 16(1):25. PubMed ID: 30943990
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.